Ipamorelin vs SLU-PP-332
Well Studied vs Emerging
compatible May preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.
Molecular Data
Ipamorelin SLU-PP-332
Weight 711.85 Da 290.32 Da
Half-life ~2 hours Under investigation (no human PK data)
Chain 5 amino acids Non-peptide small molecule
Type Growth hormone secretagogue Synthetic ERR agonist
Key Benefits
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
SLU-PP-332
01 Exercise mimetic effects without physical activity
02 12% weight loss in 28 days
03 70% increased endurance
04 25% enhanced fatty acid oxidation
05 Improved insulin sensitivity
06 Reduced hepatic steatosis
07 Cardiac protection
08 Reversal of age-related mitochondrial dysfunction
Dosing Protocols
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
SLU-PP-332
NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) / Research only - not approved for human use
Standard Metabolic Protocol 50 mg/kg (animal dosing) Twice daily
Acute Exercise Enhancement 50 mg/kg (animal dosing) Single dose 1 hour pre-exercise
Extended Treatment 50 mg/kg (animal dosing) Twice daily for 4-8 weeks
Side Effects
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
SLU-PP-332
Animal studies show favorable safety with no severe effects at therapeutic doses
Well-tolerated in rodents and canines
No liver, kidney, or cardiac toxicity documented
No lean mass loss
Does not suppress hormones or act as stimulant
Minor plasma cholesterol and liver enzyme changes in some studies
Contraindications
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications
Research Evidence
Ipamorelin SLU-PP-332
Status Well Studied Emerging
References 5 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.